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A61-year-old Vietnamese woman with type 2 diabetes mellitus was hospitalized in May2004 with chest pain. Noted were prominent tophaceous-appearing lesions on bothhands (A to C). These lesions were biopsy proven (D and E) in January 2003 to be
tendon xanthomas. Earliest available lipid values from 2003 were as follows: total cholesterol
490 mg/dl, low-density lipoprotein cholesterol 345 mg/dl, triglycerides 557 mg/dl, and high-
density lipoprotein cholesterol 34 mg/dl. Lipid-lowering medications were recommended in
2003; however, none was reported on presentation in May 2004. Therapy was initiated with
fenofibrate, atorvastatin, and colestipol. Eventually, therapy was modified to consist chronically
of Niaspan (niacin) 1,000 mg daily, ezetimibe 10 mg daily, colestipol 1,000 mg twice daily,
and rosuvastatin 40 mg daily. The patient underwent coronary artery stenting in 2005 and re-
nal artery stenting in 2006, and has known peripheral vascular disease. The tophaceous-appear-
ing tendon xanthomas showed marked diminution in size and/or resolution after 6 years of
consistent aggressive lipid-lowering therapy (F and G).
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